Semaglutide, a potent GLP-1R activator (GLP1-RA), is recommended by diabetes associations to improve glycemic control in patients with T2D and as a first-line therapy in established atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors to reduce the risk of major adverse cardiovascular events (MACE), i.e., myocardial infarction, stroke and cardiovascular death [5,6]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.